

Michele Ghidini

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/207902/michele-ghidini-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

131
papers

2,711
citations

27
h-index

48
g-index

165
ext. papers

3,828
ext. citations

4.5
avg, IF

5.42
L-index

#	Paper	IF	Citations
131	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status.. <i>Journal of Hematology and Oncology</i> , 2022 , 15, 9	22.4	0
130	Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis.. <i>Scientific Reports</i> , 2022 , 12, 1055	4.9	0
129	Development and Multicentre Validation of the Modena Score to Predict Survival in Advanced Biliary Cancers Undergoing Second-Line Chemotherapy.. <i>Cancer Management and Research</i> , 2022 , 14, 983-993	3.6	
128	Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint Inhibitors: An Unexpected Scenario. <i>Vaccines</i> , 2022 , 10, 679	5.3	
127	Nanomedicine for the Delivery of RNA in Cancer. <i>Cancers</i> , 2022 , 14, 2677	6.6	0
126	MicroRNAs as Diagnostic Tools in Hepatocellular Carcinoma. <i>Gastrointestinal Disorders</i> , 2021 , 3, 237-246	0.8	0
125	A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?. <i>Supportive Care in Cancer</i> , 2021 , 30, 2455	3.9	1
124	Post-Induction Management in Patients With Left-Sided and Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study. <i>Frontiers in Oncology</i> , 2021 , 11, 712053	5.3	3
123	Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 705-713	3.5	2
122	Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6
121	The Appropriateness of Invasive Ventilation in COVID-19 Positive Cancer Patients: Proposal of a New Prognostic Score. <i>Viruses</i> , 2021 , 13,	6.2	1
120	Association of Obesity With Survival Outcomes in Patients With Cancer: A Systematic Review and Meta-analysis. <i>JAMA Network Open</i> , 2021 , 4, e213520	10.4	29
119	How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell-Based Approaches. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
118	Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer. <i>Cancers</i> , 2021 , 13,	6.6	5
117	Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors. <i>Pharmaceutics</i> , 2021 , 13,	6.4	10
116	Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis. <i>World Journal of Methodology</i> , 2021 , 11, 95-109	1.2	1
115	The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy. <i>Current Drug Targets</i> , 2021 , 22, 1021-1033	3	2

114	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. <i>Journal of Translational Medicine</i> , 2021 , 19, 270	8.5	3
113	Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study. <i>Cancers</i> , 2021 , 13,	6.6	3
112	Population-Based Long-term Cardiac-Specific Mortality Among Patients With Major Gastrointestinal Cancers. <i>JAMA Network Open</i> , 2021 , 4, e2112049	10.4	1
111	Circulating Tumor DNA as a Biomarker for Outcomes Prediction in Colorectal Cancer Patients. <i>Current Drug Targets</i> , 2021 , 22, 1010-1020	3	
110	Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study. <i>Clinical Colorectal Cancer</i> , 2021 ,	3.8	4
109	Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC Patients Treated with Sorafenib. <i>Biomedicines</i> , 2021 , 9,	4.8	1
108	Survival of Colorectal Cancer Patients With Diabetes Mellitus: A Meta-Analysis. <i>Canadian Journal of Diabetes</i> , 2021 , 45, 186-197.e2	2.1	7
107	Triage process for the assessment of coronavirus disease 2019-positive patients with cancer: The ONCOVID prospective study. <i>Cancer</i> , 2021 , 127, 1091-1101	6.4	4
106	Micropapillary Bladder Cancer Metastatic to the Breast: A Case Report and Brief Literature Review. <i>In Vivo</i> , 2021 , 35, 453-459	2.3	1
105	Effects of hypertension on cancer survival: A meta-analysis. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13493	4.6	4
104	Advances in the pharmacological management of neutropenia in solid tumors: the advent of biosimilars. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 857-865	4	0
103	The Role and Expression of Angiogenesis-Related miRNAs in Gastric Cancer. <i>Biology</i> , 2021 , 10,	4.9	6
102	ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality. <i>Future Oncology</i> , 2021 , 17, 4607-4618	3.6	0
101	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	1
100	Metabolic disorders and the risk of cholangiocarcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021 , 15, 999-1007	4.2	1
99	Total neoadjuvant therapy for initially inoperable pancreatic cancer: A systematic review of phase 2-3 studies. <i>Radiotherapy and Oncology</i> , 2021 , 164, 13-19	5.3	1
98	Red blood cell transfusions and the survival in patients with cancer undergoing curative surgery: a systematic review and meta-analysis. <i>Surgery Today</i> , 2021 , 51, 1535-1557	3	3
97	Lactobacillus Kefiri LKF01 (Kefibios) for Prevention of Diarrhoea in Cancer Patients Treated with Chemotherapy: A Prospective Study. <i>Nutrients</i> , 2021 , 13,	6.7	5

96	1696P Incidence of influenza-like illness (ILI) in cancer patients during COVID-19: The ONCOVID prospective observational study. <i>Annals of Oncology</i> , 2020 , 31, S1001	10.3	78
95	The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. <i>Vaccines</i> , 2020 , 8,	5.3	16
94	Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	11
93	Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study. <i>Cancers</i> , 2020 , 12,	6.6	10
92	The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference. <i>International Journal of Colorectal Disease</i> , 2020 , 35, 1513-1527	3	4
91	Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2020 , 6, 1068-1071	13.4	28
90	Developing a risk assessment score for patients with cancer during the coronavirus disease 2019 pandemic. <i>European Journal of Cancer</i> , 2020 , 135, 47-50	7.5	15
89	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020 , 21, 498-508.e2	4.9	27
88	Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 931-940	4	4
87	Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020 , 12,	6.6	73
86	Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS. <i>Gastric Cancer</i> , 2020 , 23, 689-698	7.6	9
85	Coronavirus infection and immune system: An insight of COVID-19 in cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 153, 103059	7	18
84	Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options. <i>Cancer Management and Research</i> , 2020 , 12, 675-686	3.6	14
83	Renal Function Assessment Gap in Clinical Practice: An Awkward Truth. <i>Kidney and Blood Pressure Research</i> , 2020 , 45, 166-179	3.1	5
82	A systematic review of salvage therapies in refractory metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2020 , 35, 783-794	3	5
81	Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema. <i>Frontiers in Oncology</i> , 2020 , 10, 422	5.3	10
80	Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020 , 12,	6.6	10
79	Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer. <i>Genes</i> , 2020 , 12,	4.2	8

78	Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma. <i>World Journal of Gastroenterology</i> , 2020 , 26, 3542-3561	5.6	10
77	MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside. <i>Targeted Oncology</i> , 2020 , 15, 261-278	5	63
76	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. <i>European Journal of Cancer</i> , 2020 , 134, 19-28	7.5	21
75	Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells. <i>Hepatology</i> , 2020 , 72, 982-996	11.2	21
74	Total Neoadjuvant Therapy in Rectal Cancer: A Systematic Review and Meta-analysis of Treatment Outcomes. <i>Annals of Surgery</i> , 2020 , 271, 440-448	7.8	106
73	Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Journal of Immunotherapy</i> , 2020 , 43, 1-7	5	36
72	Letter of response to comments on: Developing a risk assessment score for patients with cancer during COVID-19 pandemic: A war on two fronts. <i>European Journal of Cancer</i> , 2020 , 140, 161-162	7.5	1
71	IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic Targeting. <i>Cancers</i> , 2020 , 12,	6.6	8
70	Evaluation of Prognostic Factors for Survival in Transverse Colon Cancer. <i>Cancers</i> , 2020 , 12,	6.6	3
69	A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic. <i>Cancers</i> , 2020 , 12,	6.6	11
68	Circulating Tumour DNAs and Non-Coding RNAs as Liquid Biopsies for the Management of Colorectal Cancer Patients. <i>Gastrointestinal Disorders</i> , 2020 , 2, 212-235	0.8	5
67	Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, e193531	13.4	7
66	Prognostic factors associated with survival in a large cohort of gastric cancer patients resected over a decade at a single Italian center: the Cremona experience. <i>Clinical and Translational Oncology</i> , 2020 , 22, 1004-1012	3.6	9
65	Adjuvant chemotherapy in patients with rectal cancer achieving pathologic complete response after neoadjuvant chemoradiation and surgery. <i>European Journal of Cancer</i> , 2019 , 108, 97-99	7.5	4
64	Outcome of head compared to body and tail pancreatic cancer: a systematic review and meta-analysis of 93 studies. <i>Journal of Gastrointestinal Oncology</i> , 2019 , 10, 259-269	2.8	20
63	Timing of Adjuvant Chemotherapy and Survival in Colorectal, Gastric, and Pancreatic Cancer. A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019 , 11,	6.6	25
62	Adjuvant radiotherapy for Merkel cell carcinoma: A systematic review and meta-analysis. <i>Radiotherapy and Oncology</i> , 2019 , 134, 211-219	5.3	24
61	Risk of second primary tumors in GIST survivors: A systematic review and meta-analysis. <i>Surgical Oncology</i> , 2019 , 29, 64-70	2.5	5

60	Epidemiological, clinical and pathological characteristics of gastric neoplasms in the province of Cremona: the experience of the first population-based specialized gastric cancer registry in Italy. <i>BMC Cancer</i> , 2019 , 19, 212	4.8	4
59	Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019 , 11,	6.6	45
58	Impact of tumor site on the prognosis of small bowel adenocarcinoma. <i>Tumori</i> , 2019 , 105, 524-528	1.7	6
57	Use of Antibiotics and Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies. <i>Cancers</i> , 2019 , 11,	6.6	36
56	Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality?. <i>Cancers</i> , 2019 , 11,	6.6	16
55	Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919853954	5.4	4
54	Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 2365-2373	4.9	6
53	Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919877725	5.4	8
52	Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	33
51	Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer (mGC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4043-4043	2.2	3
50	Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric cancer (mGC) with or without prior gastrectomy: Results from a phase III study (TAGS).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3-3	2.2	1
49	Immune-related adverse events (irAEs) and survival in solid tumors treated with immune checkpoint inhibitors (ICIs): A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14130-e14130	2.2	
48	Is there a correlation between clinic-pathological features, MSI, PD-L1 and survival outcomes in resected gastric cancer? Looking for optimal biomarkers.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e15566-e15566	2.2	1
47	Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14545-e14545	2.2	
46	Clinical impact of neutropenia and febrile neutropenia in mCRC pts treated with FOLFOXIRI/bevacizumab (bev): A pooled analysis of TRIBE and TRIBE2 studies.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 11591-11591	2.2	
45	Combination of radiotherapy and immunotherapy for brain metastases: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 144, 102830	7	21
44	Microsatellite Instability and Survival in Stage II Colorectal Cancer: A Systematic Review and Meta-analysis. <i>Anticancer Research</i> , 2019 , 39, 6431-6441	2.3	30
43	Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis. <i>Gastric Cancer</i> , 2019 , 22, 245-254	7.6	22

42	Biliary tract cancer: current challenges and future prospects. <i>Cancer Management and Research</i> , 2019 , 11, 379-388	3.6	27
41	Association of CDX2 Expression With Survival in Early Colorectal Cancer: A Systematic Review and Meta-analysis. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 97-103	3.8	20
40	Different Toxicity of Cetuximab and Panitumumab in Metastatic Colorectal Cancer Treatment: A Systematic Review and Meta-Analysis. <i>Oncology</i> , 2018 , 94, 191-199	3.6	23
39	Clinical and Molecular Predictors of PD-L1 Expression in Non-Small-Cell Lung Cancer: Systematic Review and Meta-analysis. <i>Clinical Lung Cancer</i> , 2018 , 19, 315-322	4.9	25
38	MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours. <i>Targeted Oncology</i> , 2018 , 13, 423-436	5	4
37	Prognostic factors associated with survival and recurrence in resectable gastric cancer: Retrospective analysis of 379 patients operated at Cremona Hospital from 2007 to 2016.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16079-e16079	2.2	
36	Prognosis of elderly gastric cancer patients after surgery: a nomogram to predict survival. <i>Medical Oncology</i> , 2018 , 35, 111	3.7	21
35	Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 1437-1448	21.7	210
34	Right Versus Left Colon Cancer: Resectable and Metastatic Disease. <i>Current Treatment Options in Oncology</i> , 2018 , 19, 31	5.4	16
33	Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS). <i>Annals of Oncology</i> , 2018 , 29, v122	10.3	5
32	FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis. <i>JAMA Oncology</i> , 2017 , 3, e170278	13.4	96
31	Overview of different available chemotherapy regimens combined with radiotherapy for the neoadjuvant and definitive treatment of esophageal cancer. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 649-660	3.8	11
30	Clinical outcome and molecular characterization of brain metastases from esophageal and gastric cancer: a systematic review. <i>Medical Oncology</i> , 2017 , 34, 62	3.7	11
29	Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies. <i>European Journal of Surgical Oncology</i> , 2017 , 43, 1607-1616	3.6	61
28	Prognostic Role of Primary Tumor Location in Non-Metastatic Gastric Cancer: A Systematic Review and Meta-Analysis of 50 Studies. <i>Annals of Surgical Oncology</i> , 2017 , 24, 2655-2668	3.1	37
27	Clinical development of mTor inhibitors for renal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 1229-1237	5.9	37
26	Characterisation of the immune-related transcriptome in resected biliary tract cancers. <i>European Journal of Cancer</i> , 2017 , 86, 158-165	7.5	34
25	First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (COIRC) phase II study. <i>Oncotarget</i> , 2017 , 8, 111795-111806	3.3	5

24	Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. <i>Hpb</i> , 2017 , 19, 741-748	3.8	33
23	Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature. <i>Breast Cancer Research and Treatment</i> , 2017 , 166, 339-349	4.4	42
22	Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials. <i>Hpb</i> , 2017 , 19, 944-950	3.8	4
21	Modified schedules of DCF chemotherapy for advanced gastric cancer: a systematic review of efficacy and toxicity. <i>Anti-Cancer Drugs</i> , 2017 , 28, 133-141	2.4	4
20	The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis. <i>European Journal of Cancer</i> , 2017 , 84, 141-148	7.5	64
19	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. <i>ESMO Open</i> , 2017 , 2, e000241	6	6
18	Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. <i>Annals of Oncology</i> , 2017 , 28, 555-561	10.3	32
17	Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2017 , 3, 211-219	13.4	380
16	The sexist behaviour of immune checkpoint inhibitors in cancer therapy?. <i>Oncotarget</i> , 2017 , 8, 99336-99346	3.9	55
15	Prognostic factors associated with survival and recurrence in resectable gastroesophageal adenocarcinoma: retrospective analysis of 497 patients operated at two Italian centers.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15588-e15588	2.2	
14	Presence of bone metastases(BM) at diagnosis is associated with poor prognosis and coagulation disorders (CD) in patients (pts) with advanced gastric cancer (AGC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15538-e15538	2.2	
13	Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. <i>Carcinogenesis</i> , 2016 , 37, 852-7	4.6	13
12	MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma. <i>British Journal of Cancer</i> , 2016 , 115, 1343-1350	8.7	20
11	Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2721-7	2.2	144
10	KRAS mutation in lung metastases from colorectal cancer: prognostic implications. <i>Cancer Medicine</i> , 2016 , 5, 256-64	4.8	26
9	Targeted therapies in gastric cancer treatment: where we are and where we are going. <i>Investigational New Drugs</i> , 2016 , 34, 378-93	4.3	14
8	What Medical Oncologist Residents Think about the Italian Speciality Schools: A Survey of the Italian Association of Medical Oncology (AIOM) on Educational, Clinical and Research Activities. <i>PLoS ONE</i> , 2016 , 11, e0159146	3.7	2
7	New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim. <i>Therapeutics and Clinical Risk Management</i> , 2016 , 12, 1009-15	2.9	6

6	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. <i>Radiotherapy and Oncology</i> , 2015 , 117, 315-21	5.3	24
5	Non-Coding RNAs in Primary Liver Cancer. <i>Frontiers in Medicine</i> , 2015 , 2, 36	4.9	29
4	A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 115-23	3.5	42
3	Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. <i>Pharmacogenomics</i> , 2011 , 12, 1641-52	2.6	36
2	Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial. <i>Chemotherapy</i> , 2011 , 57, 156-61	3.2	14
1	Obesity paradox in patients with cancer: A systematic review and meta-analysis of 6,320,365 patients		5